Hengrui Pharma(SH:600276) 2 1 Shi Ji Jing Ji Bao Dao·2025-10-15 03:35Group 1 - The recent recovery of the innovative drug concept has been observed, with related ETFs showing positive performance, particularly the Tianhong Innovative Drug ETF (517380) which saw a peak increase of nearly 2% and is currently up 1.14% [1] - The Biopharmaceutical ETF (159859) has also shown a rise of 1.19%, with a trading volume close to 70 million yuan, leading among similar products [2] - Heng Rui Medicine has received approval for multiple injectable drug clinical trials, indicating a positive development in the biopharmaceutical sector [2] Group 2 - Investment firms like CMB International and Founder Securities express optimism about the innovative drug sector, suggesting that recent market corrections may present buying opportunities [2][3] - The Tianhong Innovative Drug ETF (517380) is noted as the largest in the market, covering a wide range of innovative drugs across the Hong Kong and mainland markets [3] - The Biopharmaceutical ETF (159859) closely tracks the Biopharmaceutical Index, which includes the top 30 stocks in the sector based on market capitalization and liquidity [3]